$STOK

Stoke Therapeutics and Biogen presented long-term data at the 16th European Epilepsy Congress, showing zorevunersen's potential in treating Dravet syndrome. The Phase 1/2a and OLE studies demonstrated durable seizure reductions, cognitive and behavioral improvements, and quality of life enhancements. The Phase 3 EMPEROR study data is expected in Q3 2027, aiming to complete the U.S. NDA submission. Zorevunersen was generally well tolerated, with some patients treated for over 5 years. Dravet synd

Stoke Therapeutics (STOK) and Biogen (BIIB) presented 4-year data from Phase 1/2a studies of zorevunersen, an investigational treatment for Dravet syndrome, at the 16th European Epilepsy Congress. The data showed sustained improvements in cognition, behavior, and seizure reduction, with a generally well-tolerated safety profile. The Phase 3 EMPEROR study is ongoing, with results expected in Q3 2027.

Stoke Therapeutics (STOK) shares rose 1.4% in pre-market trading after JPMorgan initiated coverage with an Overweight rating and $40 price target. The company has 14 buy ratings, with no holds or sells, and recently completed patient enrollment in its Phase 3 EMPEROR study. STOK is trading at $31.85, 21% below its 52-week high.

Ticho Barry (CHIEF MEDICAL OFFICER) sold 4,767 shares of Stoke Therapeutics, Inc. (STOK) at an average of $32.03 ($32.01–$32.47, $0.15M total) across 2 trades on 2026-08-18.

Kaye Edward M. MD sold 12,567 shares of Stoke Therapeutics, Inc. (STOK) at an average of $32.03 ($32.01–$32.47, $0.40M total) across 2 trades on 2026-08-18.

Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR trial for zorevunersen in Dravet syndrome met enrollment targets with zero dropouts. The FDA granted breakthrough therapy designation. The study will assess seizures and Vineland-3 cognitive and behavioral endpoints. Stoke plans a rolling NDA start in Q1 2027, completing in Q3 2027.

Stoke Therapeutics (STOK) reported Phase III EMPEROR enrollment completion of 162 patients and said a Phase III readout is expected in Q3 2027. Rolling NDA submissions are planned for Q1 2027, with a potential early 2028 launch of zorevunersen. Q2 revenue was $9.3M and net loss $61.6M. Pro forma cash was about $420M.

Stoke Therapeutics (STOK) reported Q2 2026 sales of $9.33M, down from $13.82M a year earlier, with a net loss of $61.62M and basic and diluted loss per share of $0.93. For H1 2026, sales fell to $15.55M and the company swung to a net loss of $111.62M. It also filed a $57.72M shelf registration for 2,000,000 common shares tied to an ESOP.

The U.S. Space Force, via Space Systems Command, modified NSSL Phase 3 Lane 1 launch-service contracts for seven companies, raising the contract ceiling from $5.6B to $17B. Awardees include Blue Origin, Impulse Space, Relativity Federal, Rocket Lab USA, SpaceX, Stoke Space Technologies, and ULA. No funds were obligated at award.

The U.S. Space Force expanded the NSSL Phase 3 Lane 1 vendor pool to seven companies, adding Impulse Space and Relativity Federal on July 7. Initial providers were SpaceX, Blue Origin, and ULA in June 2024, with Rocket Lab and Stoke Space added in March 2025. Lane 1 supports lower-risk national security launches; SpaceX has most awarded task orders.